SOLICITATION NOTICE
B -- Generation of an endometrial cancer cell lines containing endometrial cancer specific mutations in gene FBXW7
- Notice Date
- 8/26/2016
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2016-286-DM
- Archive Date
- 9/15/2016
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a non-competitive sole source basis to Washington University, Genome Engineering and iPSC Center, One Brookings Drive, Saint Louis, MO 63130-4862; to provide generation of an endometrial cancer cell lines containing endometrial cancer specific mutations in gene FBXW7, for the National Institute of Health (NIH), National Human Genome Research Institute (NHGRI). Background: The National Institute of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Human Genome Research Institute (NHGRI), mission has expanded to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. The National Human Genome Research Institute (NHGRI), Cancer Genetics and Comparative Genomics Branch (CGCGB) seek to identify and study genes that contribute to cancer susceptibility and progression. They focus on inherited and somatic (body cell) mutations that contribute to cancer susceptibility syndromes and to the development of various aggressive cancers, including prostate, endometrial, bladder, lung, head and neck, and gastric cancers. They also study the relationship between genetic variation and cancer progression and pursue the discovery of both inherited and somatic variants that lead, specifically, to fast-growing and aggressive tumors. Purpose and Objectives: The purpose of this purchase order is for the generation of an endometrial cancer cell lines containing endometrial cancer specific mutations in gene FBXW7. These cell lines will be used by the NHGRI Reproductive Cancer Genetics Section laboratory, to analyze the cellular consequences of FBXW7 mutation in an endometrial cancer cell line. Current technologies are only allowing for overexpression of one isoform but mutations are common to all three isoforms of FBXW7. CRISPR technology is very complex. The Genome Engineering & iPSC Center (GEiC) at Washington University responded to NHGRI's initial feasibility inquiry with unmatched expertise. GEiC team was able to find guide RNAs with "good off-target profiles" that will be used to insert NHGRI researcher's mutations of interest. GEiC at Washington University will look for both homozygous and heterozygous clones and are willing to provide up to 3 clones per mutation, an important factor to test experimental reproducibility. Finally, GEic will provide two (2) recommendations for experimental controls, again demonstrating an expertise NHGRI Cancer Genetics and Comparative Genomics Branch (CGCGB), Reproductive Cancer Genetics Section hope to use for successful implementation of CRIPSR technology. This service will knock in endometrial cancer specific mutations targeting all three isoforms of the gene FBXW7 in a endometrial cancer cell line. Procurement: 1. Cell Line Evaluation (USPC-ARK-1), Quantity: One; 2. gRNA design, assembly, and validation - minimal vector, Quantity: Five; 3. Donor oligo design, Quantity: Six; 4. Donor oligo synthesis, Quantity: Six; 5. Knockin Modification Fee, Quantity: Six; 6. Phase I: confirmation in a pool of cells, Quantity: Six; 7. Phase IIA: single cell dilution cloning, expansion and screening (up to 800 wells), Quantity: Six; 8. Phase IIB: positive clone(s) expansion, genotype confirmation, and clone cryopreservation, Quantity: Six; 9. Extra modified clone, Quantity: Six; and 10. myoplasma testing (assume three clones per line), Quantity: Nineteen. Period of Performance: 12-Months Regulatory Authority : This acquisition is conducted under the authority of the Federal Acquisition Regulations (FAR) Subpart 13.106-1(b) Soliciting from a single source and is not expected to exceed the simplified acquisition threshold, only one responsible source and no other supplies or services will satisfy agency requirements. This requirement is under the SAT of $150,000.00. Statutory Authority: This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. Closing Statement: Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology and small business size standard is 1000. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-89-1 (August). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received no later than 7:30 a.m. Eastern Standard Time (EST), August 31, 2016; and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2016-286-DM, may be submitted to the National, Heart, Lung and Blood Institute, COAC Services Branch, Office of Acquisitions, Office of Management, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2016-286-DM/listing.html)
- Record
- SN04244240-W 20160828/160826235841-d31dc94a1b155449655ebe62b5a456dc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |